Q2-osavuosiraportti
39 päivää sitten‧53 min
0,5843 USD/osake
Viimeisin osinko
3,15 %
Tuotto/v
Tarjoustasot
Määrä
Osto
1 600
Myynti
Määrä
140
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Q1-osavuosiraportti | 7.5. | |
| 2025 Yhtiökokous | 27.3. | |
| 2024 Q4-osavuosiraportti | 5.2. |
Datan lähde: Morningstar, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
11.9.·Anyone have any thoughts on what Semaglutide's patent expiration in China and Canada in 2026 will mean for sales of Ozempic, Wegovy and Rybelsus? Copies in the 2 countries and Copies from Canada to the US as before with insulin?
3 päivää sitten·In Canada, at least, this is a deliberate loophole. In Canada, there is the Patented Medicine Prices Review Board (PMPRB), which is an independent federal body that regulates prices for medicines protected by patents. The legal basis is the Patent Act, which states that if a company sells a patented medicine in Canada at an "unreasonably high price", the PMPRB can intervene. This means: Price cap: When a new patented medicine comes on the market, the manufacturer must submit price information to the PMPRB. International comparison: Prices are assessed, among other things, in relation to what the medicine costs in other countries. Possibility of regulation: If the PMPRB finds the price to be unreasonably high, they can require the company to lower the price or repay "excess earnings" to the government. This only applies to patented medicines - not generics or other products. So by giving up the patent and opening up to copies, they have the right to set their own prices
3 päivää sitten·Recurring topic, few have understood this. Sensational headlines are remembered better.
10.9.·Then came another downward adjustment - was there anyone who had been warned in advance - it has fallen quite a bit since Friday. Are we going to go down 10-15% today? Outlook 2025 Expectations 10 September Expectations 6 August Operating profit growth (EBIT) at CER 4-10% 10-16% Depreciation, amortisation and impairment losses Around DKK 21 billion Around DKK 17 billion
9.9.·Tuesday's announcement by the Institute for Clinical and Economic Review (ICER) that weight loss drugs from Novo Nordisk and Eli Lilly have now become cost-effective is an important victory for the two pharmaceutical groups, as the assessment could pave the way for growth in US companies' health insurance plans for their employees. That's the conclusion of Bank of America, whose analyst Tim Anderson follows Novo Nordisk's US competitor, Eli Lilly. The independent drug watchdog last assessed in 2022 that the glp-1 drugs, which include Novo's Wegovy and Eli Lilly's Zepbound, were not cost-effective. However, the new position undermines claims that "prices are too high in relation to the clinical value they provide," says Bank of America. "It is an important and necessary step towards ensuring better employer coverage, which, admittedly, has slowed down," it says. In a draft assessment on Tuesday, ICER gave semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, the highest rating for cost-effectiveness. The same goes for archrival Eli Lilly’s tirzepatid. Prices have come down a lot over the past few years, David Rind, ICER’s chief medical officer, told Reuters, but he also pointed out that high demand means “payers have some issues with the pricing of the drugs.” ICER assessed tirzepatid as more cost-effective than Novo’s semaglutide, which it described as “promising but inconclusive.” “We know for sure that tirzepatid has greater weight loss, and we strongly suspect fewer gastrointestinal side effects,” David Rind told Reuters. “What we don’t really know is whether the cardiovascular outcomes are better, worse or the same,” he continued. Wegovy and Zepbound have both shown positive effects against serious cardiovascular events in obese people. Tim Anderson and Bank of America have a buy recommendation for Eli Lilly's stock and a price target of $900. On Tuesday, the stock rose 1.6 percent to $750, and the bank thus sees a potential of 20 percent. Novo's stock lost 2.4 percent in Denmark earlier Tuesday, but the American listing is only up 0.9 percent.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
39 päivää sitten‧53 min
0,5843 USD/osake
Viimeisin osinko
3,15 %
Tuotto/v
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11.9.·Anyone have any thoughts on what Semaglutide's patent expiration in China and Canada in 2026 will mean for sales of Ozempic, Wegovy and Rybelsus? Copies in the 2 countries and Copies from Canada to the US as before with insulin?3 päivää sitten·In Canada, at least, this is a deliberate loophole. In Canada, there is the Patented Medicine Prices Review Board (PMPRB), which is an independent federal body that regulates prices for medicines protected by patents. The legal basis is the Patent Act, which states that if a company sells a patented medicine in Canada at an "unreasonably high price", the PMPRB can intervene. This means: Price cap: When a new patented medicine comes on the market, the manufacturer must submit price information to the PMPRB. International comparison: Prices are assessed, among other things, in relation to what the medicine costs in other countries. Possibility of regulation: If the PMPRB finds the price to be unreasonably high, they can require the company to lower the price or repay "excess earnings" to the government. This only applies to patented medicines - not generics or other products. So by giving up the patent and opening up to copies, they have the right to set their own prices3 päivää sitten·Recurring topic, few have understood this. Sensational headlines are remembered better.
- 10.9.·Then came another downward adjustment - was there anyone who had been warned in advance - it has fallen quite a bit since Friday. Are we going to go down 10-15% today? Outlook 2025 Expectations 10 September Expectations 6 August Operating profit growth (EBIT) at CER 4-10% 10-16% Depreciation, amortisation and impairment losses Around DKK 21 billion Around DKK 17 billion
- 9.9.·Tuesday's announcement by the Institute for Clinical and Economic Review (ICER) that weight loss drugs from Novo Nordisk and Eli Lilly have now become cost-effective is an important victory for the two pharmaceutical groups, as the assessment could pave the way for growth in US companies' health insurance plans for their employees. That's the conclusion of Bank of America, whose analyst Tim Anderson follows Novo Nordisk's US competitor, Eli Lilly. The independent drug watchdog last assessed in 2022 that the glp-1 drugs, which include Novo's Wegovy and Eli Lilly's Zepbound, were not cost-effective. However, the new position undermines claims that "prices are too high in relation to the clinical value they provide," says Bank of America. "It is an important and necessary step towards ensuring better employer coverage, which, admittedly, has slowed down," it says. In a draft assessment on Tuesday, ICER gave semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, the highest rating for cost-effectiveness. The same goes for archrival Eli Lilly’s tirzepatid. Prices have come down a lot over the past few years, David Rind, ICER’s chief medical officer, told Reuters, but he also pointed out that high demand means “payers have some issues with the pricing of the drugs.” ICER assessed tirzepatid as more cost-effective than Novo’s semaglutide, which it described as “promising but inconclusive.” “We know for sure that tirzepatid has greater weight loss, and we strongly suspect fewer gastrointestinal side effects,” David Rind told Reuters. “What we don’t really know is whether the cardiovascular outcomes are better, worse or the same,” he continued. Wegovy and Zepbound have both shown positive effects against serious cardiovascular events in obese people. Tim Anderson and Bank of America have a buy recommendation for Eli Lilly's stock and a price target of $900. On Tuesday, the stock rose 1.6 percent to $750, and the bank thus sees a potential of 20 percent. Novo's stock lost 2.4 percent in Denmark earlier Tuesday, but the American listing is only up 0.9 percent.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1 600
Myynti
Määrä
140
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Q1-osavuosiraportti | 7.5. | |
| 2025 Yhtiökokous | 27.3. | |
| 2024 Q4-osavuosiraportti | 5.2. |
Datan lähde: Morningstar, Quartr
Q2-osavuosiraportti
39 päivää sitten‧53 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 7.8. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Q1-osavuosiraportti | 7.5. | |
| 2025 Yhtiökokous | 27.3. | |
| 2024 Q4-osavuosiraportti | 5.2. |
Datan lähde: Morningstar, Quartr
0,5843 USD/osake
Viimeisin osinko
3,15 %
Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11.9.·Anyone have any thoughts on what Semaglutide's patent expiration in China and Canada in 2026 will mean for sales of Ozempic, Wegovy and Rybelsus? Copies in the 2 countries and Copies from Canada to the US as before with insulin?3 päivää sitten·In Canada, at least, this is a deliberate loophole. In Canada, there is the Patented Medicine Prices Review Board (PMPRB), which is an independent federal body that regulates prices for medicines protected by patents. The legal basis is the Patent Act, which states that if a company sells a patented medicine in Canada at an "unreasonably high price", the PMPRB can intervene. This means: Price cap: When a new patented medicine comes on the market, the manufacturer must submit price information to the PMPRB. International comparison: Prices are assessed, among other things, in relation to what the medicine costs in other countries. Possibility of regulation: If the PMPRB finds the price to be unreasonably high, they can require the company to lower the price or repay "excess earnings" to the government. This only applies to patented medicines - not generics or other products. So by giving up the patent and opening up to copies, they have the right to set their own prices3 päivää sitten·Recurring topic, few have understood this. Sensational headlines are remembered better.
- 10.9.·Then came another downward adjustment - was there anyone who had been warned in advance - it has fallen quite a bit since Friday. Are we going to go down 10-15% today? Outlook 2025 Expectations 10 September Expectations 6 August Operating profit growth (EBIT) at CER 4-10% 10-16% Depreciation, amortisation and impairment losses Around DKK 21 billion Around DKK 17 billion
- 9.9.·Tuesday's announcement by the Institute for Clinical and Economic Review (ICER) that weight loss drugs from Novo Nordisk and Eli Lilly have now become cost-effective is an important victory for the two pharmaceutical groups, as the assessment could pave the way for growth in US companies' health insurance plans for their employees. That's the conclusion of Bank of America, whose analyst Tim Anderson follows Novo Nordisk's US competitor, Eli Lilly. The independent drug watchdog last assessed in 2022 that the glp-1 drugs, which include Novo's Wegovy and Eli Lilly's Zepbound, were not cost-effective. However, the new position undermines claims that "prices are too high in relation to the clinical value they provide," says Bank of America. "It is an important and necessary step towards ensuring better employer coverage, which, admittedly, has slowed down," it says. In a draft assessment on Tuesday, ICER gave semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, the highest rating for cost-effectiveness. The same goes for archrival Eli Lilly’s tirzepatid. Prices have come down a lot over the past few years, David Rind, ICER’s chief medical officer, told Reuters, but he also pointed out that high demand means “payers have some issues with the pricing of the drugs.” ICER assessed tirzepatid as more cost-effective than Novo’s semaglutide, which it described as “promising but inconclusive.” “We know for sure that tirzepatid has greater weight loss, and we strongly suspect fewer gastrointestinal side effects,” David Rind told Reuters. “What we don’t really know is whether the cardiovascular outcomes are better, worse or the same,” he continued. Wegovy and Zepbound have both shown positive effects against serious cardiovascular events in obese people. Tim Anderson and Bank of America have a buy recommendation for Eli Lilly's stock and a price target of $900. On Tuesday, the stock rose 1.6 percent to $750, and the bank thus sees a potential of 20 percent. Novo's stock lost 2.4 percent in Denmark earlier Tuesday, but the American listing is only up 0.9 percent.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1 600
Myynti
Määrä
140
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt